Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model

Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model

Arrhythmogenic cardiomyopathy (ACM) is a rare genetic disease associated with ventricular arrhythmias in patients. The occurrence of these arrhythmias is due to direct electrophysiological remodeling of the cardiomyocytes, namely a reduction in the action potential duration (APD) and a disturbance o...

Full description

Bibliographic Details
Main Authors: Jean-Baptiste Reisqs, Adrien Moreau, Yvonne Sleiman, Azzouz Charrabi, Antoine Delinière, Francis Bessière, Kevin Gardey, Sylvain Richard, Philippe Chevalier
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Journal of Personalized Medicine
Subjects:
arrhythmogenic cardiomyopathy
spironolactone
arrhythmias
hiPSC-CM
Online Access:https://www.mdpi.com/2075-4426/13/2/335

Internet

https://www.mdpi.com/2075-4426/13/2/335

Similar Items